Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments.

Paul A Bunn, George R Simon

Journal: Cancer investigation 2003;21(1):87-104

PMID: 12643013

Abstract

Taxanes, paclitaxel, and docetaxel have become the cornerstone of both first-line and second-line chemotherapy for advanced non-small cell lung cancer (NSCLC). Recently, several pivotal phase III randomized trials have been published. These studies and phase II trials will be discussed. Additionally, studies utilizing a taxane and radiation therapy for resectable and locally advanced NSCLC will be outlined. The article will end with a discussion on newer strategies being currently explored to improve survival in advanced NSCLC.

Address: Thoracic Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, 12002 Magnolia Drive, Tampa, FL 33612, USA.

DOI: 10.1081/cnv-120005919

Link outs

Free resources

Medical:

https://medlineplus.gov/lungcancer.html

Subscription / membership required

Full Text Sources:

https://www.tandfonline.com/doi/10.1081/cnv-120005...

MeSH Terms: Angiogenesis Inhibitors, Antineoplastic Agents, Phytogenic, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Clinical Trials as Topic, Combined Modality Therapy, Deoxycytidine, Docetaxel, Etoposide, Female, Humans, Lung Neoplasms, Male, Microtubules, Multicenter Studies as Topic, Neoadjuvant Therapy, Organoplatinum Compounds, Paclitaxel, Palliative Care, Podophyllotoxin, Randomized Controlled Trials as Topic, Salvage Therapy, Survival Analysis, Taxoids, Teniposide, Treatment Outcome, Vinblastine, Vinorelbine, Gemcitabine